Press Releases

 
Press Releases
  Date Title and Summary View
Mar 15, 2017
SAN DIEGO, March 15, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that David Moskowitz, Vice President of Strategy and Corporate Communications, is scheduled to presen...
Mar 14, 2017
SAN DIEGO, March 14, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces a collaboration with Catalyst Pharmaceuticals for the provision of Biocept's Target Selector™ p...
Mar 8, 2017
SAN DIEGO, March 8, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that President and CEO Michael W. Nall is scheduled to present a corporate overview at the 29th Annual...
Mar 7, 2017
SAN DIEGO, March 7, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, reports financial results for the three months and the full year ended December 31, 2016, and provides an update...
Feb 21, 2017
SAN DIEGO, Feb. 21, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that it will release financial results for the fourth quarter and full year ended December 31, 2016 af...
Feb 15, 2017
SAN DIEGO, Feb. 15, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces the appointment of Michael Terry to the newly created position of Senior Vice President Commercial Ope...
Feb 9, 2017
SAN DIEGO, Feb. 9, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that President and CEO Michael W. Nall has issued the following letter to stockholders: ...
Feb 6, 2017
SAN DIEGO, Feb. 6, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of clinically actionable liquid biopsy tests designed to improve the management of cancer patients, announces that President and CEO Michael W. Nall will present a corporate overview at the 19th Annual BIO CEO and Investor Conference on Monday, Febru...
Jan 19, 2017
SAN DIEGO, Jan. 19, 2017 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of clinically actionable liquid biopsy tests to improve the management of cancer patients, announces that it has been awarded Australian Patent No. 2010229924 entitled, DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS. The issued patent covers the u...
Dec 27, 2016
SAN DIEGO, Dec. 27, 2016 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of clinically actionable liquid biopsy tests designed to improve the outcomes of cancer patients, announces that Columbia University Medical Center will conduct a study to evaluate the clinical utility of the Company's Target Selector™ platfor...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase